Advertisement

Optimization of Pharmaceutical R&D Programs and Portfolios

Design and Investment Strategy

  • Zoran Antonijevic

Table of contents

  1. Front Matter
    Pages i-viii
  2. Introduction

  3. Background

    1. Front Matter
      Pages 17-17
    2. Frederic (Rick) Sax, Raymond A. Huml, Judith Ng-Cashin
      Pages 19-33
    3. Kraig F. Schulz, Sarah T. Bobulsky, Frank S. David, Nitin R. Patel, Zoran Antonijevic
      Pages 35-47
  4. Quantitative Methodology

    1. Front Matter
      Pages 81-81
    2. Zoran Antonijevic, Jim Bolognese, Carl-Fredrik Burman, Christy Chuang-Stein, Chris Jennison, Martin Kimber et al.
      Pages 83-103
    3. Jack Kloeber Jr., Alex Stojanovic, C. Kwon Kim
      Pages 123-139
    4. Cong Chen, Robert A. Beckman, Linda Z. Sun
      Pages 141-154
    5. Robert A. Beckman, Cong Chen
      Pages 155-180
  5. Zoran Antonijevic
    Pages E1-E1
  6. Back Matter
    Pages 201-202

About this book

Introduction

Very little has been published on optimization of pharmaceutical portfolios. Moreover, most of the published literature comes from the commercial perspective, where probability of technical success (PoS) is treated as fixed, and not as a consequence of development strategy or design. In this book there is a strong focus on the impact of study design on PoS, and ultimately a portfolio’s value. Design options that are discussed are dose-selection strategies, adaptive design, and enrichment. Some development strategies that are examined are indication sequencing, optimal number of programs, and optimal decision criteria.    

This book includes chapters written by authors with very broad backgrounds including financial, clinical, statistical, decision sciences, commercial, and regulatory. Many authors have long held executive positions and have been involved with decision making at a product or at a portfolio level. As such, it is expected that this book will attract a very broad audience, including decision makers in pharmaceutical R&D, commercial, and financial departments. The intended audience also includes portfolio planners and managers, statisticians, decision scientists, and clinicians.

Early chapters describe approaches to portfolio optimization from big pharma, and venture capital standpoints, focusing on finances and processes. Later chapters present selected statistical and decision analysis methods for optimizing drug development programs and portfolios. Some methodological chapters are technical; however, with a few exceptions they require a basic knowledge of statistics by a reader. 

Keywords

Decision Analysis Decision Making Optimization Pharmaceutical Portfolio Portfolio Optimization Quantitative Methods

Editors and affiliations

  • Zoran Antonijevic
    • 1
  1. 1.Cytel Inc.CambridgeUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-319-09075-7
  • Copyright Information Springer International Publishing Switzerland 2015
  • Publisher Name Springer, Cham
  • eBook Packages Business and Economics
  • Print ISBN 978-3-319-09074-0
  • Online ISBN 978-3-319-09075-7
  • Buy this book on publisher's site
Industry Sectors
Pharma
Materials & Steel
Automotive
Biotechnology
Finance, Business & Banking
Consumer Packaged Goods
Energy, Utilities & Environment
Oil, Gas & Geosciences
Engineering